CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 68 enrolled / 68 target
Drug / intervention
Tibetree Pain Relieving Plaster +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04916249
NCT04916249Phase 2ActiveMonitor (1.1/mo)
CompareCT.gov

Tibetree Pain-Relieving Plaster for Musculoskeletal Pain Among Cancer Survivors

Memorial Sloan Kettering Cancer Center·interventional·Posted Jun 7, 2021·Updated Jun 18, 2026

In Brief

A Phase 2 clinical trial evaluating Tibetree Pain Relieving Plaster and Placebo for Cancer and Remission. Active but no longer recruiting, targeting 68 participants across 7 sites.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The purpose of this study is to find out whether Tibetree Pain Relieving Plaster, an herbal pain relief patch, may be able to reduce this pain. Tibetree Pain Relieving Plaster is available as an over-the-counter (non-prescription) treatment for the temporary relief of minor aches and pains in muscles and joints. This study is the first to test this treatment in people who have had cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer, Remission
CountriesUnited States
Collaborators--

Timeline

Phase 2Active
202220232024202520262027
First PostedJun 7, 2021
Enrollment StartMay 28, 2021
Primary CompletionMay 28, 2027
TodayJul 1, 2026
Enrollment to primary: 6 yearsPosted 5.1 years agoPrimary completion in 11 months

Arms & Interventions

Tibetree pain relieving plasterexperimental

Participants with chronic musculoskeletal pain for ≥ 3 months and with BPI worst pain rated 5 or greater during the preceding week will be eligible for the study. We will enroll 66 participants with 33 patients in each arm.

Drug: Tibetree Pain Relieving Plaster
Placebo plaster groupsplacebo_comparator

Participants with chronic musculoskeletal pain for ≥ 3 months and with BPI worst pain rated 5 or greater during the preceding week will be eligible for the study. We will enroll 66 participants with 33 patients in each arm.

Other: Placebo

Interventions

Tibetree Pain Relieving Plasterdrug

Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.

Placeboother

Participants who provide informed consent in the trial will receive either the Tibetree pain relieving plaster if randomized into the intervention arm, or an identical placebo plaster if randomized into the control arm. The treatment course for both arms are identical. Participants will be instructed to apply the plaster directly to the skin overlying the area of pain for 6 hours once daily for 14 consecutive days.